Psoriasis is a chronic, systemic inflammatory skin disorder with a variable presentation that primarily affects the skin but can also have systemic implications. Although psoriasis predominantly affects the skin, its systemic nature is highlighted by its association with comorbidities, including psoriatic arthritis, cardiovascular diseases, and metabolic syndrome. The disease course varies among individuals, with flare-ups often triggered by environmental factors, stress, or infections.
Types of Psoriasis
Plaque Psoriasis
The most common form of psoriasis, plaque psoriasis, is characterized by raised, erythematous plaques covered with silvery-white scales. These plaques typically appear on the scalp, elbows, knees, and trunk, though they can develop anywhere on the body. The condition results from the accelerated growth and accumulation of keratinocytes, leading to visible scaling.
Guttate Psoriasis
Guttate psoriasis manifests as small, drop-like lesions that usually develop suddenly, often following a streptococcal throat infection. This form is more prevalent in children and young adults and may be self-limiting. Guttate psoriasis does not always evolve into chronic plaque psoriasis, although it can in some cases.
Inverse Psoriasis
Inverse psoriasis occurs in body folds such as the axillae, groin, and under the breasts. In these areas, the typical scaling is less prominent due to friction and moisture, resulting in smooth, shiny, erythematous patches. These plaques can be particularly challenging to treat because of the skin’s sensitivity and the high potential for irritation from sweat and friction.
Pustular Psoriasis
There are three subtypes of pustular psoriasis: von Zumbusch, palmoplantar pustulosis, and acropustulosis.
Von Zumbusch psoriasis is an acute, severe form of pustular psoriasis that presents with generalized pustules over red skin, often accompanied by fever and systemic symptoms.
Palmoplantar pustulosis is characterized by sterile pustules on the palms and soles, which can lead to scaling, cracking, and discomfort. Smoking is a significant risk factor for this subtype.
Acropustulosis involves painful pustules at the fingertips and toes, potentially leading to nail deformities and, in severe cases, bone changes.
Erythrodermic Psoriasis
Erythrodermic psoriasis is a rare and severe form of psoriasis, marked by widespread erythema and scaling. It is often precipitated by infections, medications, or withdrawal from systemic therapies. Patients may experience significant systemic symptoms such as fever, chills, and electrolyte disturbances, and in severe cases, hospitalization in a burn unit may be required due to fluid loss and disruption of homeostasis.
Scalp Psoriasis
Scalp psoriasis often presents similarly to seborrheic dermatitis but can be differentiated by the appearance of thicker, silvery scales. It may extend beyond the hairline and cause significant discomfort due to itching and flaking. Scalp psoriasis can lead to hair thinning if untreated.
Psoriatic Arthritis and Systemic Considerations
Psoriasis is strongly associated with psoriatic arthritis (PsA), a form of inflammatory arthritis that can occur with or without concurrent skin lesions. PsA typically involves asymmetric joint involvement, often affecting the distal joints of the hands and feet. The condition can cause pain, stiffness, and swelling, potentially leading to joint damage if left untreated.
Triggers of Psoriasis
Psoriasis flare-ups can be triggered by various factors:
Infections: Bacterial infections, especially streptococcal throat infections, can trigger guttate psoriasis.
Stress: Emotional or physical stress is a known trigger for exacerbations.
Medications: Certain medications, such as beta-blockers, lithium, and antimalarials, can precipitate or worsen psoriasis.
Skin Injury: Physical trauma to the skin (e.g., cuts, abrasions, or surgery) can induce new lesions, a phenomenon known as the Koebner response.
Environmental Factors: Both insufficient and excessive sunlight exposure can exacerbate psoriasis. Sunburns, in particular, can trigger flare-ups.
Treatment Approaches
Psoriasis is a chronic condition that currently lacks a cure. However, various treatment options can help manage symptoms, reduce flare-ups, and improve quality of life. Treatment approaches depend on the severity and extent of the disease, as well as individual patient response.
Topical Treatments
Topical therapies remain the first-line treatment for mild to moderate psoriasis:
Topical Steroids: These are commonly used to reduce inflammation and control flare-ups. The potency and formulation (e.g., cream, ointment, or gel) should be chosen based on the area of involvement and the severity of the disease.
Vitamin D Analogs: Calcipotriene and calcitriol are effective in reducing cell proliferation and are often used in combination with topical steroids for enhanced efficacy.
Coal Tar: An older treatment that can help reduce scaling and inflammation, though it is often less preferred due to its odor and potential for staining.
Topical Retinoids: Tazarotene, a topical retinoid, is used to normalize skin cell turnover. However, it can cause skin irritation when used alone, so it is often combined with emollients or topical steroids.
Salicylic Acid: Used to reduce scale thickness, often combined with other topical treatments.
Systemic Treatments
For moderate to severe psoriasis or cases resistant to topical therapies, systemic treatments may be necessary:
Methotrexate: An immunosuppressive drug that inhibits DNA synthesis, reducing the proliferation of keratinocytes. Regular monitoring of liver function and blood counts is required.
Acitretin: An oral retinoid that helps normalize skin cell turnover but has significant teratogenic risks and requires regular monitoring of liver function and lipid levels.
Cyclosporine: An immunosuppressive agent that can provide rapid relief for severe psoriasis but is limited to short-term use due to potential renal toxicity.
Biologic Agents: Biological therapies, such as adalimumab (Humira®), etanercept (Enbrel®), infliximab (Remicade®), and ustekinumab (Stelara®), target specific components of the immune system. These drugs can be highly effective for moderate to severe cases but require careful monitoring due to the risk of infections and other systemic side effects.
Phototherapy
Ultraviolet (UV) light therapy is an effective treatment for moderate to severe psoriasis. Both UVA and UVB therapies are used, often in conjunction with photosensitizing agents like psoralens (PUVA). UVB therapy is more commonly used as a stand-alone treatment and can be administered in a clinical setting or with home-use devices.
Complications and Prognosis
Psoriasis can lead to several complications, including:
Psoriatic Arthritis: A common comorbidity that can cause joint damage.
Secondary Infections: Due to the compromised skin barrier.
Psychosocial Impact: Psoriasis can lead to significant emotional distress, social stigma, and depression.
Skin Cancer: Long-term UV therapy increases the risk of skin cancer, particularly non-melanoma skin cancers.
Conclusion
Psoriasis is a multifaceted, chronic condition that requires individualized treatment strategies. Although there is no cure, advancements in topical therapies, systemic treatments, and biologic agents have significantly improved disease management and patient outcomes. Ongoing research continues to provide new insights into the pathophysiology of psoriasis, leading to the development of more targeted therapies. Regular follow-up with healthcare providers is essential for managing this systemic condition and mitigating its impact on patients’ physical and emotional well-being.
References
Griffiths, C. E. M., & Armstrong, A. W. (2020). Psoriasis. Lancet, 396(10247), 1110-1126. https://doi.org/10.1016/S0140-6736(20)31873-7
Koo, J., Lebwohl, M., & Menter, A. (2021). Phototherapy for psoriasis. Journal of the American Academy of Dermatology, 84(5), 1151-1162. https://doi.org/10.1016/j.jaad.2020.11.038
Lebwohl, M. (2017). Psoriasis treatment: Traditional therapies and new targeted approaches. Journal of the American Academy of Dermatology, 76(5), 861-871. https://doi.org/10.1016/j.jaad.2016.09.047
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., & Gordon, K. B. (2019). Guidelines of care for the management of psoriasis and psoriatic arthritis: 2019 update of the American Academy of Dermatology/National Psoriasis Foundation guideline. Journal of the American Academy of Dermatology, 81(5), 1252-1283. https://doi.org/10.1016/j.jaad.2019.06.052
Mills, S., & Siegel, M. (2020). Psoriasis and skin cancer risk. Dermatologic Clinics, 38(3), 367-373. https://doi.org/10.1016/j.det.2020.03.004
Moll, J. M., & Wright, V. (2018). Psoriasis: An overview. Rheumatology, 57(2), 6-10. https://doi.org/10.1093/rheumatology/kex420
Ogdie, A., Weiss, P., & Mody, E. (2017). Psoriatic arthritis: Epidemiology, diagnosis, and treatment. Current Rheumatology Reports, 19(9), 1-8. https://doi.org/10.1007/s11926-017-0700-3
Papp, K. A., & Menter, A. (2022). Guttate psoriasis: A review. American Journal of Clinical Dermatology, 23(3), 365-374. https://doi.org/10.1007/s40257-022-00652-4
Richmond, J., & Ginsburg, S. (2019). Psoriasis triggers and management. Cutis, 104(1), 39-45.
Sbidian, E., Chaimani, A., & Avenell, A. (2020). Systemic therapies for chronic plaque psoriasis: A systematic review and network meta-analysis. British Journal of Dermatology, 182(3), 586-602. https://doi.org/10.1111/bjd.18164
